Publications by authors named "Ros Glasspool"
Objective: To investigate quality of life (QoL) and association with surgical complexity and disease burden after surgical resection for advanced ovarian cancer in centres with variation in surgical approach.
Design: Prospective multicentre observational study.
Setting: Gynaecological cancer surgery centres in the UK, Kolkata, India, and Melbourne, Australia.
Objectives: To describe the clinical activity of metronomic cyclophosphamide in a population of patients with recurrent ovarian cancer, and to identify predictors of clinical response.
Methods: We retrospectively reviewed all patients treated at our institution with oral metronomic cyclophosphamide for relapsed ovarian cancer between January 2012 and December 2016. These were identified from electronic chemotherapy prescription records.
Cancer treatment may result in loss of ovarian function through surgical removal of the ovaries, chemotherapy or radiation. While menopausal symptoms, such as hot flushes, night sweats, sleep disturbance, memory concerns and mood issues can be extremely bothersome to some women going through menopause naturally, women who undergo an induced menopause usually experience more sudden and severe symptoms. Pain and vaginal dryness can occur whether a woman has a sexual partner or not.
View Article and Find Full Text PDFArticle Synopsis
- - Rucaparib is a potent oral inhibitor of PARP 1 and 2, showing potential effectiveness in treating advanced breast and ovarian cancers in patients with BRCA-1/2 mutations.
- - A Phase II trial found that although the objective response rate for rucaparib was relatively low (2% for IV and 15% for oral), a significant portion of patients demonstrated stable disease for over 12 weeks and some had responses lasting up to 567 days.
- - The study concluded that rucaparib is well tolerated and requires continuous dosing to achieve the best outcomes, particularly in patients with ovarian cancer.
The first version of ENGOT's Requirements for Trials Between Academic Groups and Industry Partners in Europe was published 2010. This first update integrates the experiences made by the ENGOT network and the cooperative group studies while performing, analyzing, and publishing -among others - three large phase III trials. Furthermore, progress in European legislation and its impact on clinical studies in Europe have been considered in this update process.
View Article and Find Full Text PDFBackground: Preclinical data show that belinostat (Bel) is synergistic with carboplatin and paclitaxel in ovarian cancer. To further evaluate the clinical activity of belinostat, carboplatin, and paclitaxel (BelCaP), a phase 1b/2 study was performed, with an exploratory phase 2 expansion planned specifically for women with recurrent epithelial ovarian cancer (EOC).
Methods: Thirty-five women were treated on the phase 2 expansion cohort.
Clinical trials in recurrent ovarian cancer.
Int J Gynecol Cancer
May 2011
Article Synopsis
- - The 4th Ovarian Cancer Consensus Conference took place in Vancouver in June 2010, featuring representatives from 23 research groups focused on gynecologic cancers.
- - Group C discussed recurrent ovarian cancer, addressing four key questions regarding surgery, patient population definitions, trial endpoints, and eligibility criteria for clinical trials.
- - The conference aimed to establish an international consensus on best practices for conducting large randomized trials in ovarian cancer research.